Wednesday, March 21, 2012

Is the grant of compulsory license for Nexavar to Natco - Anti Competitive and Anti Innovation?

Pricing is a strategic decision that most MNC's have to deal with, when they are targeting emerging markets. Not all MNC's are approaching emerging markets with the same strategy as Bayer. GSK has also launched cancer drugs in India, but they have kind of mastered the art of price discovery in emerging markets. They have this knack of optimizing price and volumes to maximize profits.  And all the more, none of GSK's drug has been challenged by Indian companies for compulsory licensing. To get a glimpse of their pricing strategy visit the following link   GSK - The art of Price Discovery

No comments:

Post a Comment